MUCOSIL-20

Post-LOE

acetylcysteine

Pfizer

ANDAINHALATION, ORALSOLUTION

Approved

Oct 1986

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MUCOSIL-20 (acetylcysteine) by Pfizer is reduction activity [moa]. Approved for asthma. First approved in 1986.

Drug data last refreshed 19h ago

Mechanism of Action

Reduction Activity

Indications (1)

asthma

Clinical Trials (20)

NCT05070650Phase 3Withdrawn

Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold

Started Sep 2024

Common Cold

NCT05494398Phase 2/3Enrolling By Invitation

Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Open Label

Started Mar 2024

144 enrolled

Autism Spectrum Disorder

NCT04918719Phase 2Completed

Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke

Started Nov 2023

4 enrolled

Acute Ischemic Stroke

NCT05537220Phase 3Active Not Recruiting

Oral N-acetylcysteine for Retinitis Pigmentosa

Started Oct 2023

485 enrolled

Retinitis Pigmentosa

NCT05241262Phase 1Recruiting

Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels

Started Jul 2023

18 enrolled

Mitochondrial Disease

Worked on MUCOSIL-20 at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.